Medtech IPOs Signal US Healthcare Listing Surge

Revival of Medical-Technology IPOs in the US

Medical-technology companies are playing a key role in reviving initial public offerings (IPOs) within the life-sciences sector in the United States. After a challenging year marked by regulatory uncertainty, several firms are now showing renewed interest in going public. This trend reflects a shift in investor confidence and market dynamics.

Shoulder Innovations Inc., a company specializing in shoulder surgery implants, is set to launch an IPO that could raise up to $105 million. This makes it the second medical-device company to go public in a week, following the debut of Carlsmed Inc., a spinal-surgery implant provider. The demand for Shoulder Innovations’ shares has been robust, with multiple times the available shares being sought after. Significant anchor orders from mutual funds have further bolstered the offering.

This surge in activity signals a modest recovery in the US life-sciences market. Earlier this year, several companies successfully went public, including Kestra Medical Technologies Ltd., which focuses on heart-disease monitoring devices, Beta Bionics Inc., a diabetes-focused medtech firm, and Ceribell Inc., a company that develops seizure-detection technology. All three saw positive returns on their first trading days but now trade below their IPO prices.

Carlsmed’s shares experienced a decline of 3.3% in their initial session, which has lowered expectations for Shoulder Innovations. Despite this, investors remain interested in medical-technology companies because they often generate revenue from approved products. This contrasts with biotechnology firms, where success depends heavily on trial results for unapproved drugs.

Seth Rubin, head of global equity capital markets at Stifel Financial Corp., noted that investors are more comfortable with these companies, as many have de-risked their operations. He explained that there is an opportunity to invest in high-growth companies with less risk.

Challenges in the Life Sciences Sector

Despite the recent uptick, the life sciences sector continues to face significant challenges. Historically, this sector has contributed substantially to annual US IPO volumes. However, 2025 has been relatively quiet, partly due to changes within the Food and Drug Administration (FDA) under the leadership of US Health and Human Services Secretary Robert F. Kennedy Jr.

The uncertainty surrounding regulatory changes has affected investor sentiment. According to data compiled by WHY NOT, only 11 health-care companies raising at least $50 million have gone public in the US this year, totaling $2.7 billion in proceeds. The largest IPO was Caris Life Sciences Inc.'s $568.2 million offering in May. This is well below the 18 deals in the same period last year, which raised $5.8 billion.

The current year includes just four biotech companies, marking another lean year after 10 in the corresponding period in 2024. Rubin highlighted that the challenges faced by the biotech market also affect medtech companies with significant clinical and market risks. However, he pointed out that the medtech companies currently entering the market are generally more mature and in a growth phase, making them attractive to investors.

Investor Sentiment and Market Outlook

Investor interest in medtech companies remains strong, particularly those with established products and revenue streams. This trend suggests a growing preference for companies that have already navigated the regulatory landscape and demonstrated commercial viability.

As the market continues to evolve, the performance of recent IPOs will be closely watched. While some companies may struggle to maintain their stock prices, others could capitalize on the current environment to build long-term value. The coming months will likely provide more clarity on whether this revival in medical-technology IPOs is a sustainable trend or a temporary rebound.